B
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S.,
“SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.”,
Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium.”,
Infection and immunity, vol. 63, no. 10, pp. 4099-104, 1995.
L. E. Bermudez, Kolonoski, P., Petrofsky, M., Wu, M., Inderlied, C. B., and Young, L. S.,
“Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.”,
The Journal of infectious diseases, vol. 187, no. 12, pp. 1977-80, 2003.
L. E. Bermudez, Inderlied, C. B., and Young, L. S.,
“Mycobacterium avium complex in AIDS.”,
Current clinical topics in infectious diseases, vol. 12, pp. 257-81, 1992.
L. E. Bermudez, Wu, M., Miltner, E., and Inderlied, C. B.,
“Isolation of two subpopulations of Mycobacterium avium within human macrophages.”,
FEMS microbiology letters, vol. 178, no. 1, pp. 19-26, 1999.
L. E. Bermudez, Motamedi, N., Kolonoski, P., Chee, C., Baimukanova, G., Bildfell, R. J., Wang, G., Phan, L. Tam, and S Lowell, Y.,
“The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection.”,
The Journal of infectious diseases, vol. 197, no. 11, pp. 1506-10, 2008.
L. E. Bermudez, Young, L. S., and Inderlied, C. B.,
“Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.
L. E. Bermudez, Young, L. S., and Gupta, S.,
“1,25 Dihydroxyvitamin D3-dependent inhibition of growth or killing of Mycobacterium avium complex in human macrophages is mediated by TNF and GM-CSF.”,
Cellular immunology, vol. 127, no. 2, pp. 432-41, 1990.
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S.,
“Naturally occurring antibodies against Mycobacterium avium complex.”,
Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, Parker, A., and Goodman, J. R.,
“Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway.”,
Infection and immunity, vol. 65, no. 5, pp. 1916-25, 1997.
L. E. Bermudez, Nash, K. A., Petrofsky, M., Young, L. S., and Inderlied, C. B.,
“Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.”,
The Journal of infectious diseases, vol. 174, no. 6, pp. 1218-22, 1996.
L. E. Bermudez, Wu, M., Petrofsky, M., and Young, L. S.,
“Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages.”,
Infection and immunity, vol. 60, no. 10, pp. 4245-52, 1992.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., and Young, L. S.,
“Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 12, pp. 2717-21, 1994.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.”,
The Journal of infectious diseases, vol. 156, no. 3, pp. 510-3, 1987.
L. E. Bermudez and Inderlied, C. B.,
“Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.”,
Microbial drug resistance (Larchmont, N.Y.), vol. 3, no. 3, pp. 277-82, 1997.
L. E. Bermudez, Petrofsky, M., Inderlied, C. B., and Young, L. S.,
“Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.”,
The Journal of antimicrobial chemotherapy, vol. 36, no. 4, pp. 641-6, 1995.